By Mark Bello
Legal Examiner
Due largely to drug makers’ aggressive direct-to-consumer advertising campaigns, testosterone replacement therapy (TRT) has become a big business projected to reach profits of $5 billion by 2017. But, huge profits should not come with a huge price to pay for consumers.
The FDA said that testosterone replacement therapy (TRT) has only been approved for treating men who have hypogonadism, a form of abnormally low testosterone caused by injury or medical illness, yet many advertisements encourage older men to use testosterone replacement therapy if they are experiencing decreased sex drive, weight gain, depression or lack of energy. While use of testosterone drugs, such as AndroGel has increased dramatically over the past ten years, concerns have emerged in recent months about serious and potentially life-threatening side effects.
Read more: http://farmingtonhills.legalexaminer.com/uncategorized/deceitful-marketing-tactics-wont-prove-manhood/